Enwei Pharmaceutical Co., Ltd. (SHE:301331)

Market Cap	2.44B -21.2%
Revenue (ttm)	829.24M -6.7%
Net Income	37.78M -27.4%
EPS	0.36 -31.2%
Shares Out	101.88M
PE Ratio	66.85
Forward PE	n/a
Dividend	1.03 (4.30%)
Ex-Dividend Date	May 28, 2026

Volume	4,462,668
Open	23.78
Previous Close	23.79
Day's Range	23.28 - 24.25
52-Week Range	18.87 - 33.50
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 26, 2026

About Enwei Pharmaceutical

Enwei Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines and chemical drugs in China. The company offers drugs in the areas of gynecology, pediatrics, respiratory, stomatology, digestive, cardiovascular, hepatobiliary, and dermatology under the Jieeryin, Haowayou, and Likeshu brands. It also provides products for cold and fever relief, dental care, warming/nourishing/tonic purposes, and other uses; ointments, suppositories, capsules, effervescent tablets, and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1986
• Employees: 1,501
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301331

Financial Performance

In 2025, Enwei Pharmaceutical's revenue was 900.77 million, an increase of 10.91% compared to the previous year's 812.13 million. Earnings were 51.94 million, an increase of 38.53%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 13, 2026

Data Sources Report a data error